



18 March 2016

(16-1594)

Page: 1/2

Committee on Technical Barriers to Trade

Original: English

### NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

1.	<b>Notifying Member:</b> <u>JAPAN</u> <b>If applicable, name of local government involved (Article 3.2 and 7.2):</b>
2.	<b>Agency responsible:</b> Ministry of Health, Labour and Welfare <b>Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:</b>
3.	<b>Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other:</b>
4.	<b>Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):</b> Pharmaceutical products (HS: 30)
5.	<b>Title, number of pages and language(s) of the notified document:</b> Partial amendment to the Minimum Requirements for Biological Products (1 page, in English)
6.	<b>Description of content:</b> The Minimum Requirements for Biological Products is to be partially amended to add the standard for two vaccine products and a blood product to be newly approved.
7.	<b>Objective and rationale, including the nature of urgent problems where applicable:</b> To establish the standard for manufacturing process, properties, quality, storage and others of drugs to which special attention must be paid for the attainment of public health and sanitation (biological products)  Protection of human health or safety
8.	<b>Relevant documents:</b> The act on securing quality, efficacy and safety of pharmaceuticals, medical devices, regenerative and cellular therapy products, gene therapy products, and cosmetics. This amendment will be published in " <i>KAMPO</i> " (Official Gazette) when adopted.
9.	<b>Proposed date of adoption:</b> The same day as the approval of the said vaccine products and blood product  <b>Proposed date of entry into force:</b> The same day as the approval of the said vaccine product
10.	<b>Final date for comments:</b> 21 March 2016

**11. Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:**

Japan Enquiry Point  
International Trade Division  
Economic Affairs Bureau  
Ministry of Foreign Affairs  
Fax: (+81 3) 5501 8343  
E-mail: [enquiry@mofa.go.jp](mailto:enquiry@mofa.go.jp)

[https://members.wto.org/crnattachments/2016/TBT/JPN/16\\_1158\\_00\\_e.pdf](https://members.wto.org/crnattachments/2016/TBT/JPN/16_1158_00_e.pdf)